120th General Meeting of the KCS

Type Symposium
Area Current Trends in Organic Chemistry II: Organic Materials & Supramolecular Chemistry
Room No. Room 304+305+306
Time FRI 09:00-:
Code ORGN2-1
Subject Bispecific Antibody Conjugates for Cancer Immunotherapy
Authors Chan Hyuk Kim
Department of Life Science, KAIST, Korea
Abstract Cancer immunotherapy has been drawing growing attention as a novel promising therapeutic modality for cancer. Unlike conventional chemo- or radiotherapy, immunotherapy treats cancer by unleashing the suppressed activity of the patient’s own immune system and harnessing its power to fight cancer, to achieve robust anti-tumor responses while minimizing collateral damages to normal tissues. Among several immunotherapeutic approaches, T cell-based immunotherapeutics such as bispecific antibodies and chimeric antigen receptor (CAR) T cells have generated unprecedented responses in clinics, and have become promising therapeutic modalities for the treatment of refractory cancers. In this talk, I will briefly discuss our recent efforts on developing novel approaches for T cell-based immunotherapeutic using novel bispecific antibody conjugates, in particular PSMA-targeting small molecule antibody conjugate and switchable CAR-T platform.
E-mail kimchanhyuk@kaist.ac.kr